UNSPSC 51112201: Bleomycin/sodium chloride

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class AN200. This VA Drug Class (AN200) classifies this compound as belonging to the group ANTINEOPLASTIC ANTIBIOTICS.

UNSPSC 51112201 Bleomycin/sodium chloride is a Commodity code that covers pharmaceutical preparations combining bleomycin and sodium chloride solution, typically used in oncology treatment protocols. State and local governments procure this code primarily through health agencies, state Medicaid programs, and public hospital systems that maintain formularies for cancer care and related therapeutic applications. The recent activity under this code reflects broader state health procurement focused on managing pharmaceutical costs and access through direct vendor engagement rather than traditional pharmacy benefit manager intermediation.

The Texas Health and Human Services Commission posted a Request for Information (RFI) in March 2026 to explore direct-to-manufacturer prescription programs, with a response deadline of April 3, 2026, seeking vendor capabilities for establishing direct contracts with state health plans outside existing pharmacy benefit manager and group purchasing organization arrangements. This RFI represents preliminary market intelligence gathering rather than a binding competitive solicitation, designed to inform the state's future procurement strategy for pharmacy benefit management before issuing a formal Request for Proposal with established financial and temporal parameters. The source identifies no other recent state or local opportunities under this code, suggesting limited visible activity at the Commodity level for this specific pharmaceutical formulation during the current procurement period.